Document Detail


Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters.
MedLine Citation:
PMID:  12717685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The goal of this study concerned the pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients by data pattern analysis from flow cytometric immunophenotype, cytogenetic, and clinical data. METHODS: Sixty-seven parameters of AML patients at diagnosis were classified for predictive information by algorithmic data sieving using iteratively self optimizing triple matrix data pattern analysis (http://www.biochem.mpg.de/valet/classif1.html). RESULTS: Pretherapeutic predictive values for nonsurvival within five years and two years were 100.0% and 83.2%, respectively, compared to 13.9% and 47.4% for the prediction of survival at five years and two years, respectively. At diagnosis, five-year nonsurvivors showed increased patient age and higher concentration of cells in the analyzed specimen, as well as increased levels of % CD2, CD4, CD13, CD36, and CD45 positive AML blasts. Two-year nonsurvivors were characterized by a data pattern of increased patient age and levels of % CD4, CD7, CD11b, CD24, CD45, TH126, and HLA-DR positive AML blasts and decreased levels of % CD1, CD65, CD95, and TC25 positive AML blasts. Cytogenetic abnormalities were not selected for the optimized discriminatory data patterns. CONCLUSIONS: The comparatively accurate pretherapeutic identification of high-risk AML patients may prove useful for the development of individualized therapy protocols in stratified clinical patients groups.
Authors:
G Valet; R Repp; H Link; A Ehninger; M Gramatzki M;
Related Documents :
16493615 - Role of cyp2d6, cyp1a1, cyp2e1, gstt1, and gstm1 genes in the susceptibility to acute l...
24460065 - Both gender and concurrent chronic lymphocytic thyroiditis may influence the nuclear te...
19781775 - Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q2...
8371595 - Monitoring of adult b-cell lineage acute lymphoblastic leukemia: validation of a simple...
17950085 - Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin...
8574715 - Antibiotic prophylaxis for ercp: a randomized clinical trial comparing ciprofloxacin an...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Cytometry. Part B, Clinical cytometry     Volume:  53     ISSN:  1552-4949     ISO Abbreviation:  Cytometry B Clin Cytom     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-04-28     Completed Date:  2004-02-20     Revised Date:  2009-12-11    
Medline Journal Info:
Nlm Unique ID:  101235690     Medline TA:  Cytometry B Clin Cytom     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4-10     Citation Subset:  IM    
Copyright Information:
Copyright 2003 Wiley-Liss, Inc.
Affiliation:
Max-Planck-Institut für Biochemie, Martinsried, Germany. valet@biochem.mpg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Computational Biology
Flow Cytometry*
Humans
Immunophenotyping
Leukemia, Myeloid / mortality*,  pathology*
Predictive Value of Tests
Prognosis
Risk Factors
Survival Analysis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytomics in predictive medicine.
Next Document:  Immunophenotyping is an independent factor for risk stratification in AML.